Core Viewpoint - ST Hengjiu is facing delisting risk due to failing to meet financial indicators for 2024, with 2025 performance forecasts indicating continued negative values, potentially leading to termination of stock listing [1][3] Financial Performance - The company expects revenue for 2025 to be between 280 million and 330 million yuan, showing significant year-on-year growth, but anticipates a net loss attributable to shareholders of between 34 million and 50 million yuan, primarily due to declining prices of OPC products, rising costs, and increased expenses [5] Compliance and Legal Issues - ST Hengjiu is currently facing investor claims due to violations in information disclosure, with potential legal proceedings that could impact the company's reputation and financial situation [4] Stock Market Reaction - Recent stock price fluctuations reflect market concerns regarding the delisting risk associated with the company's financial performance [2][6] Reporting Obligations - The company is required to disclose quarterly reports and interim announcements, with the first quarter performance for 2026 expected to be released in April [6]

证券代码：002808 证券简称：*ST 恒久 公告编号：2026-005 苏州恒久光电科技股份有限公司 关于公司股票可能被终止上市的第二次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、苏州恒久光电科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日披露了《关于公司股票被实施退市风险警示及继续被实施其他风险警示的 提示性公告》（公告编号：2025-023），因公司 2024 年度经审计的利润总额、 净利润、扣除非经常性损益后的净利润为负值，且扣除后的营业收入低于 3 亿元， 根据《深圳证券交易所股票上市规则》的相关规定，公司股票交易已于 2025 年 4 月 25 日起被实施"退市风险警示"。若 2025 年经审计后的相关指标触及《深 圳证券交易所股票上市规则》第 9.3.12 条规定的相关情形，公司股票将存在被 终止上市的风险。 2、公司于 2026 年 1 月 31 日披露了《2025 年度业绩预告》（公告编号： 2026-002），公司预计 2025 年度利润总额、净利润、扣除非经常性损益后的净 利润均为 ...

Core Viewpoint - *ST Hengjiu announced that due to negative audited profit totals, net profits, and net profits after deducting non-recurring gains and losses for the fiscal year 2024, and revenue below 300 million yuan, its stock will be subject to "delisting risk warning" starting April 25, 2025 [1] Financial Performance - The company expects that for the fiscal year 2025, the profit total, net profit, and net profit after deducting non-recurring gains and losses will all be negative [1] - The estimated revenue after deductions for 2025 is projected to be approximately 280 to 330 million yuan [1] Delisting Risk - Due to the incomplete audit of the 2025 annual financial data, the revenue amount remains uncertain, and if the audited results meet certain criteria, the company's stock may face the risk of being terminated from listing [1]

Macro Dynamics - The People's Bank of China (PBOC) Shanghai Headquarters emphasizes the need for reasonable growth in financing throughout the year, particularly in the first quarter, and balanced allocation of credit [2] - Beijing's financial system aims to enhance support for key areas such as expanding domestic demand, technological innovation, and small and micro enterprises, while also improving risk management and regulatory effectiveness [3] Financial Institutions - Ningbo Bank's vice president, Fu Wensheng, has received approval for his appointment from the Ningbo Financial Regulatory Bureau [6] Market Data - In January 2026, A-share new account openings reached 4.9158 million, a month-on-month increase of 89% and a year-on-year increase of 213% compared to January 2025 [5] - The Shenzhen Component Index rebounded over 2%, with more than 4,800 stocks in the market rising, while the Shanghai Composite Index and ChiNext Index also saw gains [8] - As of February 2, the total margin balance in the two markets decreased by 5.93 billion yuan [11] Company Dynamics - *ST Hengji received a court ruling for a performance compensation payment of 175 million yuan [12] - Beijing's first land auction of 2026 raised 8.56 billion yuan, with ByteDance acquiring a commercial financial service land in Haidian for 2.8 billion yuan [13] - Hongfu Han signed a contract worth 480 million yuan with Guangdong Quanxiang for the supply of robots and related products, which is expected to significantly impact the company's future performance [14] - Ningde Times has repurchased 15.9908 million A-shares for a total amount of 4.386 billion yuan as of January 31, 2026 [17] - Kweichow Moutai has repurchased 416,900 shares for a total payment of 571 million yuan as of the end of January 2026 [18]

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

证券代码：002808 证券简称：*ST恒久 公告编号：2026-004 苏州恒久光电科技股份有限公司 关于收到民事判决书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示: 1、案件所处的诉讼阶段：一审已判决。 依照《中华人民共和国公司法》（2018年修正）第一百三十七条，《中华人 民共和国民事诉讼法》第六十七条、第一百四十五条、第一百四十七条之规定， 判决如下： 林章威于本判决生效之日起十日内向苏州恒久光电科技股份有限公司支付 业绩补偿款17506.43万元。 如果未按本判决指定的期间履行给付金钱义务，应当依照《中华人民共和国 1 2、上市公司所处的当事人地位：原告。 3、涉案的金额：业绩补偿款 17,506.43 万元及案件受理费和公告费 91.7522 万元。 4、对上市公司损益产生的影响：本次诉讼案件尚处于一审判决阶段，公司 目前暂无法判断本案对公司本期利润或期后利润的影响。 苏州恒久光电科技股份有限公司（以下简称"公司"）于近日收到江苏省苏 州市中级人民法院送达的《民事判决书》[(2025)苏05民初826号]，相关具体情 况如下 ...

证券代码：002808 证券简称：*ST 恒久 公告编号：2026-003 苏州恒久光电科技股份有限公司 关于公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、苏州恒久光电科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日披露了《关于公司股票被实施退市风险警示及继续被实施其他风险警示的 提示性公告》（公告编号：2025-023），因公司 2024 年度经审计的利润总额、 净利润、扣除非经常性损益后的净利润为负值，且扣除后的营业收入低于 3 亿元， 根据《深圳证券交易所股票上市规则》的相关规定，公司股票交易已于 2025 年 4 月 25 日起被实施"退市风险警示"。若 2025 年经审计后的相关指标触及《深 圳证券交易所股票上市规则》第 9.3.12 条规定的相关情形，公司股票将存在被 终止上市的风险。 2、根据公司于本公告同日披露的《2025 年度业绩预告》（公告编号： 2026-002），公司预计 2025 年度利润总额、净利润、扣除非经常性损益后的净 利润均为负值，扣除后营业收入约 ...

Financial Performance - The company expects a total profit loss of between 37 million and 53 million yuan for the fiscal year 2025, compared to a loss of 41.96 million yuan in the previous year[4] - The net profit attributable to shareholders is projected to be a loss between 34 million and 50 million yuan, compared to a loss of 47.10 million yuan in the previous year[4] - The revenue for 2025 is estimated to be between 280 million and 330 million yuan, a significant increase from 161.75 million yuan in the previous year[4] - The company’s basic earnings per share are expected to be a loss between 0.126 yuan and 0.186 yuan per share, compared to a loss of 0.175 yuan per share in the previous year[4] - The company’s total equity attributable to shareholders is projected to be between 240 million and 260 million yuan at the end of the fiscal year, down from 285.88 million yuan at the end of the previous year[5] Revenue and Expenses - The increase in revenue is primarily attributed to the acquisition of Shanghai Jingxin Technology Co., Ltd.[7] - The average selling price of the company's OPC products has decreased due to market conditions, while material procurement costs have risen[7] - Sales and management expenses have increased to accelerate the development of new business[7] Risks and Compliance - The company faces a risk of delisting if the audited financial indicators for 2025 fall below the thresholds set by the Shenzhen Stock Exchange[8] - The financial data provided is preliminary and has not yet been audited, with final figures to be disclosed in the 2025 annual report[8]

针对公司股票异常波动，公司对有关事项进行了核实，现对有关核实情况说 明如下： 1、公司目前经营情况正常，内外部经营环境未发生重大变化。 2、公司前期披露的信息不存在需要更正、补充之处。 证券代码：002808 证券简称：*ST恒久 公告编号：2026-001 苏州恒久光电科技股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 苏州恒久光电科技股份有限公司（以下简称"公司"）股票于 2026 年 1 月 19 日、1 月 20 日和 1 月 21 日连续三个交易日收盘价格涨幅偏离值累计超过 12%， 根据《深圳证券交易所交易规则》的有关规定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 3、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 4、公司、控股股东和实际控制人不存在关于本公司的应披露而未披露的重 大事项，或处于筹划阶段的重大事项。 5、股票异常波动期间，控股股东、实际控制人未发生买卖公司股票的行为。 6、公司不存在违反公平信息披露规定的 ...

Core Viewpoint - *ST Hengjiu announced that there has been unusual volatility in its stock trading, but the company's current operating conditions remain normal, and there have been no significant changes in the internal and external operating environment [1] Group 1 - The company has issued a notice regarding abnormal fluctuations in its stock trading [1] - The operating conditions of the company are reported to be normal [1] - There have been no significant changes in the internal and external operating environment [1]